Sort
82,697 grants matching “vaccine development”
Regulatory immune cell therapy, promotion of tolerance and underlying mechanisms in NHP renal transplantation
$1,468,504Angus W Thomson · University Of Pittsburgh At Pittsburgh · U19 · FY2019 · AI
Regulatory immune cell therapy, promotion of tolerance and underlying mechanisms in NHP renal transplantation
$1,468,504Angus W Thomson · University Of Pittsburgh At Pittsburgh · U19 · FY2021 · AI
Novel nanoparticulate adjuvants to enhance HIV-1 Env specific mucosal antibody responses
$1,468,408Sudhir Pai Kasturi · Emory University · R01 · FY2021 · AI
Host-parasite-vector interactions during malaria transmission
$1,468,198Joel Vega-Rodriguez · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Colorado AIDS Clinical Trials Unit
$1,467,763Thomas B. Campbell · University Of Colorado Denver · UM1 · FY2013 · AI
Immunostimulatory Patch To Enhance Biodefense Vaccines
$1,467,294Iomai Corporation · U01 · FY2005 · AI
Collaborative Research: Effects of land-use, predation and management on wildlife contact and Brucella transmission in the Yellowstone Ecosystem
$1,467,104Scott R Creel · Montana State University · · FY2010 · BIO
Lambda Genetic Networks and Lambda Red-Mediated Recombination
$1,467,086Donald Court · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Targeting PD-1 Pathway for Functional Cure of AIDS
$1,467,069Rama Rao Amara · Emory University · R37 · FY2020 · AI
VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT
$1,466,770Vanderbilt University · U01 · FY2005 · AI
Human monoclonal antibodies targeting infectious pathogens
$1,466,586Joshua Hoong Yu Tan · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Stanford/UNC Biomimetic U19 Research Center
$1,466,585Calvin J Kuo · Stanford University · U19 · FY2025 · AI
BLOOD GROUP ANTIGENS IN HEALTH AND DISEASE
$1,466,502New York Blood Center · P50 · FY2004 · HL
Mechanisms Of Humoral Evasion
$1,466,332Tongqing Zhou · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
PPG: HOST VIRUS INTERACTIONS IN HCoV-SARS INFECTIONS
$1,466,243University Of Iowa · P01 · FY2004 · AI
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency
$1,465,945Michael A Pulsipher · Children'S Hospital Of Los Angeles · U01 · FY2020 · AI
DEVELOPMENT OF LIVE-ATTENUATED VIRUS VACCINE PLATFORM AGAINST HEMORRHAGIC FEVER CAUSING ARENAVIRUSES
$1,465,710Texas Biomedical Research Institute · · FY2019 · Defense Health Agency
Cultivation, Nature, Ecology and Pathogenicity of the Uncultivable Oral Microbiom
$1,465,407Floyd E Dewhirst · Ada Forsyth Institute, Inc. · R01 · FY2015 · DE
Herpesvirus Pathogenesis and Vaccine Development
$1,465,303Jeffrey Cohen · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Role of HIV Envelope Proteins In Viral Replication and HIV Pathogenesis
$1,464,833Claudia Cicala · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Defining Factors Controlling HIV Rebound
$1,464,427Jerome A. Zack · University Of California Los Angeles · P01 · FY2021 · AI
Acute HIV Infection: Implications for vaccine design
$1,464,387Marcus Altfeld · Massachusetts General Hospital · P01 · FY2010 · AI
KSHV Persistence and Pathogenesis
$1,463,663Jae U Jung · University Of Southern California · P01 · FY2013 · CA
Lymphocyte Dynamics
$1,463,485William Paul · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
Task X7: Preparedness for Testing NIAID Priority Vaccines for Infectious Diseases
$1,463,441Norman Kneteman · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2013 · AI